Idan kun ji labarin retatrutida Kuma idan kuna mamakin ko yana taimakawa sosai tare da asarar nauyi, anan shine mafi cikakken jagora don samun ku cikin sauri. Wannan gwajin gwajin daga Eli Lilly yana cikin tabo don sa aiki mai ƙarfi Wannan binciken yana mayar da hankali kan hanyoyi uku na hormonal na ci da kuma metabolism, da kuma bayanan gwaji wanda ke nuna bambance-bambance idan aka kwatanta da magungunan yanzu. A cikin layi na gaba, za mu gaya muku abin da yake, yadda yake aiki, menene sakamakon da ya nuna, da abin da ya kamata ku yi la'akari kafin ku yi farin ciki sosai. Hakanan zaku sami kwatancen tare da semaglutide da tirzepatide da cikakken bayani game da matsayin sa na tsari. Duk waɗannan ana gabatar da su ta hanya mai amfani kuma a cikin Sifananci bayyananne, don kada ku rasa wani abu.
Da farko, yana da mahimmanci a fayyace wurin farawa: retatrutide bai riga ya amince da hukumomin da suka dace ba kuma ana iya amfani dashi kawai a gwaji na asibiti. Duk da haka, bayanan da aka buga kuma aka gabatar a taro suna da ban mamaki, tare da asarar nauyi kusan 24% a cikin ƙasa da shekara guda a cikin manya masu kiba ba tare da ciwon sukari ba. Ana bayyana wannan yuwuwar ta hanyar tsarin aikin sa na "tuku" da ƙarin tasirin rayuwa wanda ya wuce asarar nauyi. A kowane hali, muna magana ne game da magani mai ƙarfi wanda ke buƙatar ... kulawar likita da kuma dabarun dosing a hankali don inganta haƙuri, saboda abubuwan da ke faruwa na gastrointestinal sun wanzu kuma suna dogara da kashi, kodayake yawancin suna da sauƙi ko matsakaici a cikin tsanani.
Menene retatrutide kuma ta yaya yake aiki?
Retatrutide (LY-3437943) shine agonist na "sau uku" wanda aka tsara don kunna GLP-1, GIP, da masu karɓar glucagon lokaci guda. Wannan haɗin ba na haɗari ba ne: kwaikwayi waɗannan hormones na hanji da pancreatic suna nufin ... rage ci, jinkirin zubar da ciki, da ƙara yawan kashe kuzariWannan dabarar aiki sau uku na iya fassara zuwa ƙarin asarar nauyi da ingantaccen bayanin martaba na cardiometabolic. Eli Lilly ne ya ƙera shi, ƙwayar ƙwayar cuta tana da nufin haɗa mafi kyawun duniyoyi uku waɗanda muka riga muka sani daban tare da magungunan guda ɗaya ko biyu.
Masanin ilimin lissafi yana da sauti. Analogs GLP-1 yana daidaita sukarin jini kuma yana haɓaka satiety; GIP agonism ya bayyana don ƙara ƙarin kayan aikin rayuwa; da glucagon receptor stimulating iya inganta thermogenesis da substrate motsi. Tare, waɗannan tasirin suna nema rage cin abinci, rage jin yunwa kuma "kashe" da yawaDon haka ba abin mamaki bane cewa karatun Mataki na 2 ya haifar da kanun labarai.
Gwaje-gwaje na asibiti: nawa nauyi ya ɓace kuma abin da ke faruwa ga lafiyar jiki
A cikin gwaji na Mataki na 2 a cikin manya ko masu kiba ba tare da ciwon sukari ba, mafi girman adadin da aka kimanta (12 MG) ya sami matsakaicin asarar nauyi kusa da 24% a makonni 48Girman girma da sauri ya ba da mamaki har ma masu binciken, waɗanda suka lura cewa yawancin mahalarta ba su kai ga wani wuri mai nauyi ba a ƙarshen binciken, yana nuna cewa rufin tasiri na iya zama dan kadan mafi girma tare da tsawon lokacin magani.
Baya ga asarar nauyi, akwai gagarumin tasiri akan alamomin cardiometabolic: a rage triglyceride har zuwa 40%raguwa a cikin apoC-III na kusan 38%, raguwa a cikin kitsen hanta, ingantaccen hawan jini, da alamun haɓakar insulin. A wasu nazarin, matan sun cimma nasara asarar nauyi har zuwa 29%, adadi mai ban mamaki wanda ke ƙarfafa ra'ayin cewa aikin sau uku zai iya ba da ƙarin fa'ida a wasu bayanan martaba.
Bayanan ba'a iyakance ga mutanen da ba su da ciwon sukari. A cikin binciken marasa lafiya da ke da nau'in ciwon sukari na 2, mahalarta da aka bi da su tare da retatrutide sun ɓace a kusa da [wani kaso na] 17% na nauyin jiki a cikin watanni tarakuma kusan kashi ɗaya bisa uku sun daidaita matakan glucose na jininsu yayin jiyya. Wannan batu yana da mahimmanci saboda a cikin nau'in ciwon sukari na 2, samun irin wannan raguwar nauyi yakan fi wahala. A cikin rukunin placebo, ta hanyar, asarar nauyi ya kasance a kusa da 2,1%, wanda ke nuna bambanci tsakanin sa baki mai aiki da ƙungiyar kulawa.
A ƙarshe, ƙididdiga ta amsa ɗaya ta cancanci ambaton: har zuwa a 83% na waɗanda suka karɓi mafi girman kashi sun sami asarar ≥15% na farkon nauyi. Waɗannan ƙofa ne masu mahimmanci na asibiti waɗanda ke da alaƙa da haɓaka masu dacewa cikin haɗarin cardiometabolic.
Sashi da jagororin: me yasa farawa ƙasa da haɓaka a hankali
A cikin Mataki na 2, an gwada allurai na mako-mako na 1, 4, 8, da 12 MG, amma yawancin mahalarta ba su fara kai tsaye tare da adadin da aka yi niyya ba. An zaɓi wata hanya ta daban. farawa dabarun a 2 MG / mako tare da haɓakawa a hankali don inganta haƙuri, musamman game da tasirin gastrointestinal. Wannan tsarin "kadan kadan" ya rage yawan fita da kuma inganta riko.
Ta yaya wannan ke fassara a aikace? Idan babu takardar bayanan fasaha na hukuma (saboda har yanzu ba a amince da shi ba), mafi yawan tsare-tsare masu ma'ana sun yi kama da wannan misali: makonni 1-4 zuwa 2 MG5-8 makonni a 4 MG; sa'an nan daidaita zuwa 8 ko 12 MG dangane da juriya da amsa. A cikin nazarin, haɓakar kashi yana da alaƙa da babban abin da ya faru na mummunan sakamako na gastrointestinal, don haka adadin titration ya kamata ya zama daidaikun mutum.
Muhimmiyar nuance game da mitar: yawancin takaddun bayanai da sanarwar manema labarai sun bayyana gudanar da mako-makoKoyaya, wasu labaran labarai sun ambaci jadawalin mako-mako biyu. Tun da ka'idojin da aka buga suna dalla-dalla tsarin tsarin mako-mako, da alama wannan zai zama ma'auni, ko da yake za mu jira cikakken sakamako na Mataki na 3 da kuma shawarar tsari don sanin adadin ƙarshe.
Tsaro da mummunan tasiri: abin da aka riga aka sani
Gabaɗayan bayanin martabar aminci na retatrutide, bisa bayanan Mataki na 2, yayi daidai da na magungunan da ke da alaƙa. Abubuwan da suka fi faruwa akai-akai sun kasance tashin zuciya, amai, gudawa, da maƙarƙashiyaWaɗannan su ne irin wannan nau'in magunguna kuma mafi kusantar faruwa tare da manyan allurai ko yayin haɓakar kashi. Haka kuma an ga ciwon kai, gajiya, da sauran illoli. hawan jini na hanta enzymes, gabaɗaya na matsakaici zuwa matsakaicin ƙarfi.
Wasu rahotannin gwaji sun nuna karuwa a cikin bugun zuciya da rashin daidaituwa ba a la'akari da tsanani. Kamar yadda yake tare da kowane haɓakar ƙwannafi, maɓalli ya ta'allaka ne a cikin daidaitawa a hankali da saka idanu na asibiti, daidaita ƙimar haɓaka da matakan abinci don rage alamun narkewar abinci.
Yana da mahimmanci a sanya wannan a cikin mahallin tare da masu kwatanta. Semaglutide, alal misali, yana raba yawancin waɗannan tasirin, kuma hukumomi sun yi gargadin lokuta da ba kasafai ba na baya-bayan nan na ischemic optic neuropathyBugu da ƙari, muna magana ne game da yanayin da ba a saba ba, amma suna kwatanta dalilin da yasa saka idanu da bayanin haƙuri ke da mahimmanci a cikin hanyoyin kwantar da hankali na yau da kullum.
Kasancewa, matsayin tsari da lokutan da ake tsammani
Tun daga yau - tare da bayanan bayanan daga Yuli 2025 - retatrutida Ba shi da yarda Babu FDA ko hukumomin Turai da suka amince da shi. Sabili da haka, amfani da shi yana iyakance ga gwaje-gwajen asibiti da aka sarrafa, inda yake da doka da daidaitacce. Kamfanin ya gabatar da nazari na Mataki na 2 a taron ADA na 2023 (Yuni 23-26) kuma yana da shirye-shirye masu gudana don tabbatar da inganci da aminci a cikin yawan jama'a.
Yaushe zai iya zuwa? Hasashen jama'a ya bambanta: wasu majiyoyi suna yin hasashe da karshen 2025 ko farkon 2026yayin da wasu ke sanya sararin sama tsakanin 2026 y 2027Har sai an kammala gwaji na Mataki na 3 kuma an tantance ma'aunin haɗarin fa'ida, ba za a amince da shi ba. Idan wani ya ba da damar "samun" a wajen gwajin asibiti, yi hankali: ba shi da izini don siyarwa.
Retatrutide tare da semaglutide da tirzepatide
Semaglutide shine agonist mai karɓa na GLP-1 tare da dogon tarihi. An yarda da shi a cikin 2017 don ciwon sukari kuma tun 2021 an nuna shi don [mai zuwa]. na kullum nauyi kulaA cikin manya ba tare da ciwon sukari ba, zaku iya cimma kusan guda ɗaya 15% asarar nauyi a cikin makonni 68Mafi yawan illolinsa sune gastrointestinal (jikin ciki, amai, gudawa) da kuma abubuwan da suka faru kamar su pancreatitis ko gastroparesis an bayyana su, baya ga gargadin NAION da aka ambata.
Tirzepatide ya haɗu da GLP-1 da GIP gonism. Yana da izini a cikin Amurka da Turai (da farko don ciwon sukari; daga baya, don kiba kamar Zepbound). Gwaji irin su SURPASS sun nuna... asarar har zuwa 20% a cikin makonni 72Kuma ko da yake bayanin martabar haƙurinsa yayi kama da na GLP-1, a cikin manyan allurai an lura da raguwar raguwa (alal misali, tare da 15 MG), dalla-dalla don yin la'akari da aikin asibiti.
Dangane da bayanan farko da ake samu, retatrutide shine mafi inganci don matsakaicin asarar nauyi, sannan tirzepatide ya biyo baya sannan kuma semaglutide. Bugu da ƙari, akwai alamun da ke bayarwa fa'idar metabolism mai fa'ida (lipids, mai hanta, ji na insulin). Duk da haka, yana da mahimmanci a tuna cewa retatrutide har yanzu yana cikin lokacin tabbatarwa kuma ba za a iya kwatanta shi ba "kai-da-kai" har sai an sami gwaje-gwajen kai-da-kai ko ingantaccen bincike-bincike tare da ma'auni iri ɗaya.
Wanene zai iya amfana kuma menene asibitocin ke tsammanin?
Bayanan martaba waɗanda zasu iya amfana mafi yawan irin wannan nau'in jiyya sune manya tare da kiba ko kiba tare da cututtukaWannan gaskiya ne musamman ga waɗanda ba su amsa ga GLP-1 analogues ko dual agonists ba. A cikin mutanen da ke da nau'in ciwon sukari na 2, tasirin dual akan glucose na jini da nauyi shima babban fa'ida ne. Duk da haka, shirin dole ne ya zama daidaikun mutane: akwai bambance-bambance a cikin haƙuri, abubuwan da za a yi la'akari da su, da kuma abubuwan da suka fi dacewa a asibiti (misali, hanta mai kitse, hauhawar jini, ko dyslipidemia).
Yayin da ake jiran amincewa, cibiyoyi na musamman da yawa suna shirya ka'idoji don aiwatar da su nan gaba, wasu ma a manyan biranen Amurka. A Spain, ƙungiyoyin sarrafa nauyi irin su asibitin MediQuo Weight Loss Clinic Suna zaɓar hanyoyin da aka keɓance, wanda wani lokaci ya haɗa da auriculotherapy don rasa nauyiTare da abinci mai gina jiki, halayya, da bibiyar likita, wannan muhimmin tushe ne don dacewa da duk wani magani na harhada magunguna. Idan kuna sha'awar hanyar jagorar ƙwararru, zaku iya samun ƙarin bayani a [adreshin hanyar haɗin yanar gizo/shafi]. www.mediquo.com/clinica-perdida-de-peso.
Jagorar mai amfani mai amfani: mahimman ra'ayoyi kafin farawa
A matsayin magani mai ƙarfi, retatrutide yana buƙatar dabarun dabara. Hanyar da ta fi dacewa, bisa ga abin da aka lura a cikin gwaji, ita ce a fara a 2 mg / mako da haɓakawa a hankali, lura da alamun narkewa, hydration, da jagororin abinci (ƙananan abinci, ƙarancin mai, fifikon furotin) yayin haɓaka. Idan karuwa yana daɗaɗa haƙuri sosai, za'a iya kiyaye kashi na baya don ƙarin makonni da yawa kafin yunƙurin mataki na gaba.
Adadin da aka yi niyya (4, 8, ko 12 MG) zai dogara ne akan yadda kuke amsawa da kuma yawan illar da kuke fuskanta. A ƙarshe, "mafi kyawun wuri" shine mafi ƙarancin kashi da zaku iya jurewa. rasa nauyi mai dorewa ba tare da lalata ingancin rayuwa ba. Tare da shaidar yanzu, babu gajerun hanyoyi: kiyaye sauye-sauyen salon rayuwa yana da mahimmanci don ƙarfafa sakamako da kare yawan tsoka.
Tambayoyi akai-akai
Menene adadin farawa na yau da kullun? A cikin Mataki na 2, yawancin sun fara tare da 2 mg mako-mako kuma a hankali sun karu zuwa 4, 8, ko 12 MG. Wannan ƙarancin farawa yana raguwa tashin zuciya da sauran tasirin GI hade da saurin karuwa.
Sau nawa ake gudanar da shi? Takardun gwajin ya bayyana jadawalin mako-makoWasu shahararrun wallafe-wallafen da aka ambata gudanarwa na mako-mako, amma cikakkun ka'idoji sun kasance mako-mako; dole ne mu jira adadin da aka yarda da shi don tabbatar da hakan.
Yau aka amince? A'a. Retatrutida har yanzu ana kan bincike kuma ba shi da izini FDA ko hukumomin Turai ba su amince da shi ba. Amfani da shi yakamata a iyakance ga gwaji na asibiti. Wasu hasashe na jama'a suna ba da yuwuwar amincewa tsakanin ƙarshen 2025 da 2027, muddin bayanan Mataki na 3 ya dace.
Shin yana da kyau fiye da semaglutide? Nazarin mataki na 2 ya nuna mafi girma nauyi asara a cikin ƙasan lokaci idan aka kwatanta da semaglutide. Koyaya, kwatancen kai tsaye da bayanan dogon lokaci tare da an riga an amince da retatrutide (lokacin da ya zama samuwa) sun rasa bayyana wannan dalla-dalla.
Kuma idan aka kwatanta da tirzepatide (Mounjaro/Zepbound)? Tirzepatide mai hanawa ne mai dual-action (GLP-1/GIP), yayin da retatrutide shine mai hana aikin sau uku (GLP-1/GIP/glucagon). Bayanan farko sun yarda da retatrutide dangane da kashi. asarar nauyiAmma kuma, za a buƙaci gwaje-gwaje na kwatankwacinsu da gogewar duniyar gaske.
Shin yana aiki don "kitsen ciki"? Gwaji sun nuna raguwa a cikin jimillar kitsen hanta, tare da asarar nauyi mai yawa. Daidai rarraba Adadin asarar mai (ciki da sauran wurare) na iya bambanta daga mutum zuwa mutum, amma haɓakawa a cikin kewayen kugu da alamomin rayuwa suna tallafawa fa'idodi a cikin kitsen visceral.
Shin ya halatta a same shi a wajen gwaji? Amfani da shi doka ne kawai a binciken asibiti. Kowane tashar madadin A wajen wannan mahallin yana da haɗari kuma mai yuwuwar zamba.
Shin Retatrutida daidai yake da Mounjaro (tirzepatida)? A'a. Suna kama da yin aiki akan GLP-1 da GIP, amma retatrutide yana ƙarawa glucagon receptor agonismwanda zai iya bayyana wasu ƙarin tasiri da aka lura.
Fa'idodi da iyakancewa a yau
Daga cikin fa'idodin sanannen su ne mafi girma asarar nauyi a cikin ƙasan lokaciHar ila yau, binciken ya bayyana fa'idodin fa'idodi masu yawa (lipids, hanta mai kitse, hawan jini, jin daɗin insulin) da alamun ingantaccen adana ƙwayar tsoka a wasu mahalarta. Wannan haɗin gwiwar yana ba da shawara mafi mahimmanci ga tsarin kiba wanda ya wuce kawai "ganin sikelin ya ragu."
A gefen iyakance, yana da wani drawback cewa Ba a yarda baKoyaya, bayanan dogon lokaci sun rasa kuma haƙuri yana da canji, tare da tasirin GI wanda zai iya buƙatar haɓakar ƙarar hankali. Bugu da ƙari, kamar yadda yake tare da duk kiba pharmacotherapy, mafi kyawun aikinsa yana faruwa lokacin Yana haɗuwa da halaye isasshen abinci mai gina jiki, aikin jiki da barci, kuma tare da goyon bayan hali.
Idan kuna la'akari da hanyar taimakon magunguna, nemi ƙungiyoyi masu gogewa a cikin magungunan kiba da ƙa'idar bin ƙa'ida. Duka a cikin ƙasa da na duniya, akwai riga da asibitocin da ke shirye-shiryen aiwatar da sababbin hanyoyin kwantar da hankali da zarar an yarda da su, kuma ayyukan asarar nauyi kamar MediQuo na iya zama farkon farawa. zana wani keɓaɓɓen tsari ba tare da rasa maganin asibiti ba.
Hoton gaba ɗaya da aka zana ta gwaji yana da kyakkyawan fata: retatrutide a halin yanzu yana jagoranci a cikin ingantaccen dangi idan aka kwatanta da tirzepatide da semaglutide a cikin manya ba tare da ciwon sukari ba, yana ƙara fa'idodi masu mahimmanci na rayuwa; diddigin Achilles iri daya ne da ko da yaushe a wannan ajin: jurewar narkewar abinci da buqatar sikeliMakullin kowane sabon abu ya ɓace: Tabbatarwa na Mataki na 3 da ainihin duniya, ƙwarewar hannu tare da ƙayyadaddun fasaha. Har sai lokacin, haƙuri, tunani mai mahimmanci, da goyan bayan ƙwararru sune mafi kyawun haɗin kai don kewaya wannan filin mai ban sha'awa amma mai buƙata da tabbaci.